Can-Fite BioPharma Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Motti Farbstein
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 26 Ben Gurion Street Ramat Gan Israel 5257346
- IPO Date
- Sep 22, 2005
- Website
- canfite.com
- Similar Companies
- Business
- Can-Fite BioPharma Ltd. is an Israeli clinical-stage biopharmaceutical company specializing in the development of oral, small molecule therapeutics targeting cancer, liver, inflammatory, and metabolic diseases. The company utilizes its proprietary platform technology focused on the Gi protein-associated A3 adenosine receptor (A3AR), which is highly expressed in pathological cells involved in these diseases while showing low expression in normal cells. Can-Fite’s main drug candidates include Piclidenoson (CF101), an oral treatment for psoriasis currently in Phase III clinical trials; Namodenoson, under Phase III study for hepatocellular carcinoma (liver cancer) and Phase IIb trials for non-alcoholic steatohepatitis (NASH), also progressing in a Phase II pancreatic cancer trial; and CF602, a preclinical candidate targeting sexual dysfunction. These drug candidates exhibit an excellent safety profile, with clinical experience encompassing close to 2,000 patients. Recent major developments at Can-Fite include advancing its drug pipeline through key clinical milestones in 2025, with Namodenoson achieving over 50% enrollment in the Phase IIa pancreatic cancer trial and receiving compassionate use approval from the FDA. The company participates actively in industry events such as BioFIT 2025 to pursue veterinary partnerships for Namodenoson, following a previous successful veterinary licensing deal for Piclidenoson with Vetbiolix, potentially valued at $325 million in royalties. Additionally, Can-Fite completed a $5 million public offering in mid-2025 to fund ongoing research and clinical initiatives. Clinical breakthroughs include a patient with advanced hepatocellular carcinoma treated with Namodenoson on compassionate use, showing 9 years overall survival with complete response and remaining cancer-free. Namodenoson holds Orphan Drug and Fast Track designations by both the FDA and European authorities, underscoring its regulatory progress. Can-Fite operates primarily in Israel with clinical trials and regulatory engagements spanning Europe and the United States. The company focuses on oncology, liver diseases, inflammatory conditions, and metabolic disorders, serving patient populations in these therapeutic areas globally. Founded in 1992 and headquartered in Petach Tikva, Israel, Can-Fite maintains a fully integrated pharmaceutical discovery and clinical development model. Its latest strategic initiatives emphasize expansion into veterinary oncology, leveraging Namodenoson's anti-tumor potential, and strengthening partnerships with major animal health companies such as Elanco and Zoetis to commercialize veterinary applications of its advanced therapeutics. Overall, Can-Fite BioPharma Ltd. delivers a pipeline of orally bioavailable, targeted therapies with robust clinical and regulatory progress, supported by strategic financial actions and pioneering veterinary market expansions in recent years. The company continues to advance its mission focusing on novel small molecule drugs for difficult-to-treat diseases, targeting significant unmet medical needs with solid clinical evidence and an expanding global footprint.
Company News
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients
Wall Street is Watching These Biotechs
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market